Analysts expect Skye Bioscience, Inc. to report revenue of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Skye Bioscience, Inc. to report earnings per share of -1.09 for Q3 26, against a range of -1.19 to -0.99. The most recent reported quarter, Q2 26, came in at -2.16, a 13.7% miss against the -1.90 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.80 | -1.92 | -2.24 | -3.52 | -2.56 | -2.88 | -2.56 | -2.16 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -1.83 | -2.16 | -2.04 | -2.51 | -2.43 | -2.28 | -2.46 | -1.71 | -0.99 | -1.02 | -1.39 | -1.52 | -0.97 | -1.08 | -2.70 | -2.81 | ||||||||||
| Low Estimate | -1.99 | -2.40 | -2.26 | -2.95 | -2.79 | -2.74 | -2.66 | -2.09 | -1.19 | -1.18 | -1.61 | -1.78 | -1.03 | -1.24 | -3.02 | -3.37 | ||||||||||
| Consensus Estimate | -1.91 | -2.28 | -2.15 | -2.73 | -2.61 | -2.51 | -2.56 | -1.90 | -1.09 | -1.10 | -1.50 | -1.65 | -1.00 | -1.16 | -2.86 | -3.09 |